Janus Henderson Group
ARRY

Janus Henderson Group’s Array Biopharma Inc ARRY Stock Holding History

Janus Henderson Group’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100,000
Closed -$675K – 868
2016
Q3 		$675K Buy
+100,000
New +$387K 0.01% 728

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Janus Henderson Group's ARRY Position: Q4 2016 in Review

Janus Henderson Group sold out of Array Biopharma Inc (ARRY) in Q4 2016, closing a stake of 100,000 shares — an estimated $675K sold.

Janus Henderson Group first reported a position in ARRY in Q3 2016 and held it in 1 quarter. The position peaked at $675K in Q3 2016. 167 funds tracked by Wall St. Rank hold ARRY as of Q4 2016.

  • Janus Henderson Group reported no remaining Array Biopharma Inc position as of Q4 2016 after selling out during the quarter.
  • Janus Henderson Group sold 100,000 Array Biopharma Inc shares in Q4 2016, an estimated $675K.
  • Janus Henderson Group first reported a position in Array Biopharma Inc in Q3 2016 and held it in 1 quarter.
  • Janus Henderson Group's Array Biopharma Inc position peaked at $675K in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2016.

Based on Janus Henderson Group's 13F filing for Q4 2016, filed 30 Jan 2017.